文献速递前列腺癌

基于MRI的前列腺穿刺活检风险计算器:前瞻性洛约拉大学多参数MRI(PLUM)与前列腺活检协作组(PBCG)风险计算器的开发与比较

A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
PubMed 文献 · BJU Int · 2022-07-11

研究开发并验证了纳入多参数MRI(mpMRI)的前列腺癌风险计算器PLUM,并与PBCG风险计算器比较。在训练队列、内部验证队列和外部验证队列中,PLUM对临床显著前列腺癌的AUC均显著优于PBCG;PBCG易过度预测而PLUM校准良好。在15%阈值概率下,PLUM每100例可避免13.8例活检而PBCG仅2.7例,且不漏诊临床显著前列腺癌。

要点

  • PLUM风险计算器在训练、内部验证和外部验证队列中对临床显著前列腺癌的AUC分别为85.9%、88.2%和83.9%,均显著优于PBCG。
  • PBCG风险计算器易过度预测,而PLUM风险计算器校准良好。
  • 在15%阈值概率下,PLUM每100例可避免13.8例活检而PBCG仅2.7例,且不漏诊临床显著前列腺癌。

核心结论

  • 基于mpMRI的PLUM风险计算器对临床显著前列腺癌的判别能力显著优于PBCG风险计算器,并与其他基于mpMRI的风险计算器相比具有优势。
  • 使用PLUM风险计算器可在共同决策中避免很大一部分活检,同时维持对临床显著前列腺癌的最佳检出。

研究设计与样本

  • 前瞻性洛约拉大学mpMRI(PLUM)前列腺穿刺活检队列纳入2015年至2020年未诊断前列腺癌且在活检前接受mpMRI的男性。
  • 训练队列674例(47.8%前列腺癌,30.9%临床显著前列腺癌),内部验证队列336例,外部验证队列371例,外部验证数据来自另一机构。
  • 采用二元逻辑回归探索标准临床和mpMRI变量(前列腺体积、前列腺影像报告和数据系统第2.0版病灶),最终PLUM风险计算器基于多项逻辑回归模型。

主要发现

  • 在训练队列中,PLUM风险计算器与PBCG风险计算器检测临床显著前列腺癌的AUC分别为85.9%与66.0%(P < 0.001)。
  • 在内部验证队列中,PLUM风险计算器与PBCG风险计算器的AUC分别为88.2%与67.8%(P < 0.001);在外部验证队列中分别为83.9%与69.4%(P < 0.001)。
  • 在15%阈值概率下,PLUM风险计算器与PBCG风险计算器每100例患者分别可避免13.8例与2.7例活检,且均未漏诊临床显著前列腺癌。
  • 在漏诊7.5%临床显著前列腺癌的成本水平下,PLUM风险计算器可避免41.0%(566/1381)的活检,而PBCG风险计算器为19.1%(264/1381)。
  • PLUM风险计算器与斯坦福前列腺癌计算器(SPCC)比较AUC为84.1%与81.1%(P = 0.002),与MRI-欧洲前列腺癌筛查随机研究(ERSPC)风险计算器比较AUC为84.5%与82.6%(P = 0.05)。

关键数值与推荐

  • PLUM风险计算器在训练队列、内部验证队列和外部验证队列中对临床显著前列腺癌的AUC分别为85.9%、88.2%和83.9%,PBCG风险计算器分别为66.0%、67.8%和69.4%(P均 < 0.001)。
  • 在15%阈值概率下,PLUM风险计算器与PBCG风险计算器每100例患者分别可避免13.8例与2.7例活检。
  • 在漏诊7.5%临床显著前列腺癌的成本水平下,PLUM风险计算器可避免41.0%(566/1381)的活检,PBCG风险计算器为19.1%(264/1381)。

临床怎么用

  • 作者认为,在共同决策中使用PLUM风险计算器可避免很大一部分活检,同时维持对临床显著前列腺癌的最佳检出。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop and validate a prostate cancer (PCa) risk calculator (RC) incorporating multiparametric magnetic resonance imaging (mpMRI) and to compare its performance with that of the Prostate Biopsy Collaborative Group (PBCG) RC. PATIENTS AND METHODS: Men without a PCa diagnosis receiving mpMRI before biopsy in the Prospective Loyola University mpMRI (PLUM) Prostate Biopsy Cohort (2015-2020) were included. Data from a separate institution were used for external validation. The primary outcome was diagnosis of no cancer, grade group (GG)1 PCa, and clinically significant (cs)PCa (≥GG2). Binary logistic regression was used to explore standard clinical and mpMRI variables (prostate volume, Prostate Imaging-Reporting Data System [PI-RADS] version 2.0 lesions) with the final PLUM RC, based on a multinomial logistic regression model. Receiver-operating characteristic curve, calibration curves, and decision-curve analysis were evaluated in the training and validation cohorts. RESULTS: A total of 1010 patients were included for development (N = 674 training [47.8% PCa, 30.9% csPCa], N = 336 internal validation) and 371 for external validation. The PLUM RC outperformed the PBCG RC in the training (area under the curve [AUC] 85.9% vs 66.0%; P < 0.001), internal validation (AUC 88.2% vs 67.8%; P < 0.001) and external validation (AUC 83.9% vs 69.4%; P < 0.001) cohorts for csPCa detection. The PBCG RC was prone to overprediction while the PLUM RC was well calibrated. At a threshold probability of 15%, the PLUM RC vs the PBCG RC could avoid 13.8 vs 2.7 biopsies per 100 patients without missing any csPCa. At a cost level of missing 7.5% of csPCa, the PLUM RC could have avoided 41.0% (566/1381) of biopsies compared to 19.1% (264/1381) for the PBCG RC. The PLUM RC compared favourably with the Stanford Prostate Cancer Calculator (SPCC; AUC 84.1% vs 81.1%; P = 0.002) and the MRI-European Randomized Study of Screening for Prostate Cancer (ERSPC) RC (AUC 84.5% vs 82.6%; P = 0.05). CONCLUSIONS: The mpMRI-based PLUM RC significantly outperformed the PBCG RC and compared favourably with other mpMRI-based RCs. A large proportion of biopsies could be avoided using the PLUM RC in shared decision making while maintaining optimal detection of csPCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Patel HD, Koehne EL, Shea SM, et al. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators. BJU Int. 2022. PMID: 35733400. doi:10.1111/bju.15835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。